Investigational drugs for treatment of juvenile idiopathic arthritis

References

• Webb K, Wedderburn LR. Advances in the treatment of polyarticular juvenile idiopathic arthritis. Curr Opin Rheumatol. 2015;27:505–510.
   PubMed Web of Science ®Google Scholar
• Thierry S, Fautrel B, Lemelle I, et al. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81:112–117.
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–392.
   PubMed Web of Science ®Google Scholar
• Rigante D, Bosco A, Esposito S. The etiology of juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2015;49:253–261.
   PubMed Web of Science ®Google Scholar
• Hahn YS, Kim JG. Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis. Korean J Pediatr. 2010;53:921–930.
   PubMedGoogle Scholar
• Hawtree S, Muthana M, Wilson AG. The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes. Biochem Soc Trans. 2013;41:783–788.
   PubMed Web of Science ®Google Scholar
• Wulffraat NM. A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis. Expert Opin Drug Saf. 2015;14:1961–1967.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–2219.
   PubMed Web of Science ®Google Scholar
• Evereklioglu C, Er H, Türköz Y, et al. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease. Mediators Inflamm. 2002;11:87–93.
   PubMed Web of Science ®Google Scholar
• Woo P. Cytokines and juvenile idiopathic arthritis. Curr Rheumatol Rep. 2002;4:452–457.
   PubMedGoogle Scholar
• Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465–482.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:1792–1802.
   PubMed Web of Science ®Google Scholar
• Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43:1849–1857.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557–567.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.
   PubMed Web of Science ®Google Scholar
• Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9:47–52.
   PubMed Web of Science ®Google Scholar
• Rigante D. The protean visage of systemic autoinflammatory syndromes: a challenge for inter-professional collaboration. Eur Rev Med Pharmacol Sci. 2010;14:1–18.
   PubMed Web of Science ®Google Scholar
• Federico G, Rigante D, Pugliese AL, et al. Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand J Rheumatol. 2003;32:312–314.
   PubMed Web of Science ®Google Scholar
• Snegireva LS, Kostik MM, Caroli F, et al. Failure of tocilizumab treatment in a CINCA patient: clinical and pathogenic implications. Rheumatology (Oxford). 2013;52:1731–1732.
   PubMed Web of Science ®Google Scholar
• Ilowite NT, Prather K, Lokhnygina Y, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:2570–2579.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65:2486–2496.
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747–754.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–2406.
   PubMed Web of Science ®Google Scholar
• Tarp S, Amarilyo G, Foeldvari I, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55:669–679.
   PubMed Web of Science ®Google Scholar
• Halili MA, Andrews MR, Sweet MJ, et al. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem. 2009;9:309–319.
   PubMed Web of Science ®Google Scholar
• Faraco G, Pittelli M, Cavone L, et al. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis. 2009;36:269–279.
   PubMed Web of Science ®Google Scholar
• Brogdon JL, Xu Y, Szabo SJ, et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 2007;109:1123–1130.
   PubMed Web of Science ®Google Scholar
• Grabiec AM, Krausz S, De Jager W, et al. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol. 2010;184:2718–2728.
   PubMed Web of Science ®Google Scholar
• Vojinovic J, Damjanov N, D’Urzo C, et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:1452–1458.
   PubMed Web of Science ®Google Scholar
• A multicenter, open label, dose finding study to evaluate efficacy and safety of givinostat administered in two different doses in patients with poly JIA not adequately responding to the standard treatment. Identifier n. NCT01261624. Available from: www.clinicaltrial.gov.
   Google Scholar
• Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998;338:161–165.
   PubMed Web of Science ®Google Scholar
• Bumgardner GL, Hardie I, Johnson RW, et al. Phase III Daclizumab Study Group. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation. 2001;72:839–845.
   PubMed Web of Science ®Google Scholar
• Yeh S, Wroblewski K, Buggage R, et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun. 2008;31:91–97.
   PubMed Web of Science ®Google Scholar
• Gallagher M, Quinones K, Cervantes-Castañeda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91:1341–1344.
   PubMed Web of Science ®Google Scholar
• Kotaniemi K, Kautiainen H, Karma A, et al. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology. 2001;108:2071–2075.
   PubMed Web of Science ®Google Scholar
• Abu Samra K, Maghsoudlou A, Roohipoor R, et al. Current treatment modalities of JIA-associated uveitis and its complications: literature review. Ocul Immunol Inflamm. 2016;24:431–439.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Mingels A, Heinz C, et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol. 2007;17:743–748.
   PubMed Web of Science ®Google Scholar
• Sharma SM, Ramanan AV, Riley P, et al. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis. 2007;66:840–841.
   PubMed Web of Science ®Google Scholar
• Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319–324.
   PubMed Web of Science ®Google Scholar
• Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res. 2010;62:821–825.
   PubMed Web of Science ®Google Scholar
• Henderson LA, Zurakowski D, Angeles-Han ST, et al. Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J. 2016;14:9.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A. 1999;96:7462–7466.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology. 2005;112:764–770.
   PubMed Web of Science ®Google Scholar
• Sen HN, Levy-Clarke G, Faia LJ, et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol. 2009;148:696–703.
   PubMed Web of Science ®Google Scholar
• Li H-W, Xie Y, Li F, et al. Effect of miR-19a and miR-21 on the JAK/STAT signaling pathway in the peripheral blood mononuclear cells of patients with systemic juvenile idiopathic arthritis. Exp Ther Med. 2016;11:2531–2536.
   PubMed Web of Science ®Google Scholar
• Lin Y-T, Wang C-T, Gershwin ME, et al. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev. 2011;10:482–489.
   PubMed Web of Science ®Google Scholar
• Ju JH, Heo YJ, Cho ML, et al. Modulation of STAT3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells. Arthritis Rheum. 2012;64:3543–3552.
   PubMed Web of Science ®Google Scholar
• Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015;34:75–82.
   PubMed Web of Science ®Google Scholar
• Kurowska-Stolarska M, Alivernini S, Ballantine LE, et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA. 2011;108:11193–11198.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Haupt S, Kreuzer JT, et al. Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:1265–1274.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Gerdes S, Gläser R, et al. Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman. Acta Derm Venereol. 2016. DOI:10.2340/00015555-2491.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Servoli S, et al. Tofacitinib for the treatment of psoriasis. Expert Opin Pharmacother. 2016;17:1421–1433.
   PubMed Web of Science ®Google Scholar
• Iwata S, Tanaka Y. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2016;12:1047–1057.
   PubMed Web of Science ®Google Scholar
• An open-label multiple dose study to evaluate the pharmacokinetics, safety and tolerability of CP-690,550 in pediatric patients from 2 to less than 18 years of age with juvenile idiopathic arthritis (JIA). Identifier n. NCT01513902. Available from: www.clinicaltrial.gov.
   Google Scholar
• Long-term safety study of Tofacitinib in patients with juvenile idiopathic arthritis. Identifier n. NCT01500551. Available from: www.clinicaltrial.gov.
   Google Scholar
• Efficacy study of tofacitinib in pediatric JIA population. Identifier n. NCT02592434. Available from: www.clinicaltrial.gov.
   Google Scholar
• Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2:247–256.
   PubMedGoogle Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–1523.
   PubMed Web of Science ®Google Scholar
• Pappas DA, John A, Curtis JR, et al. Dosing of intravenous tocilizumab in a real-world setting of rheumatoid arthritis: analyses from the Corrona Registry. Rheumatol Ther. 2016;3:103–115.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67:1424–1437.
   PubMed Web of Science ®Google Scholar
• Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY part A trial. Ann Rheum Dis. 2014;73:1626–1634.
   PubMed Web of Science ®Google Scholar
• An open-label, sequential, ascending, repeated dose-finding study of Sarilumab, administered with subcutaneous (SC) injection in children and adolescents aged 2 to 17 years with polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) followed by an extension phase. Identifier n. NCT02776735. Available from: www.clinicaltrial.gov.
   Google Scholar
• Rigante D, Cantarini L. The systemic-onset variant of juvenile idiopathic arthritis needs to be recorded as an autoinflammatory syndrome: comment on the review by Nigrovic. Arthritis Rheumatol. 2014;66:2645.
   PubMed Web of Science ®Google Scholar
• A study of the safety and efficacy of CNTO 148 (golimumab) in children with juvenile idiopathic arthritis (JIA) and multiple joint involvement who have poor response to methotrexate (GO KIDS). Identifier n. NCT01230827. Available from: www.clinicaltrial.gov.
   Google Scholar
• Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomized, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110–1117.
   PubMed Web of Science ®Google Scholar
• A study of subcutaneously administered RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis. Identifier n. NCT01904279. Available from: www.clinicaltrial.gov.
   Google Scholar
• A study of subcutaneously administered tocilizumab in participants with systemic juvenile idiopathic arthritis. Identifier n. NCT01904292. Available from: www.clinicaltrial.gov.
   Google Scholar
• A study to evaluate the pharmacokinetic and safety of tocilizumab (RoActemra/Actemra) in participants less than 2 years old with active systemic juvenile idiopathic arthritis. Identifier n. NCT01455701. Available from: www.clinicaltrial.gov.
   Google Scholar
• Pharmacokinetics, efficacy and safety of abatacept administered subcutaneously (sc) in children and adolescents with active polyarticular juvenile idiopathic arthritis (pJIA) and inadequate response (IR) to biologic or non biologic disease modifying anti-rheumatic drugs (DMARDs). Identifier n. NCT01844518. Available from: www.clinicaltrial.gov.
   Google Scholar